Trump Announces Major Drug Pricing Agreement Aimed At Lowering Costs – Full Article

Under the terms described by the White House, AstraZeneca will provide “most-favored-nation,” or MFN, pricing to all state Medicaid programs, meaning that U.S. patients will pay no more than the lowest price available for the same drugs in other developed countries. The administration said the agreement could save American taxpayers hundreds of millions of dollars annually.

“For many years, Americans have paid the highest prices anywhere in the world for prescription drugs,” Trump said. “Today, AstraZeneca is committing to offer all of their prescription medications to Medicaid at the most-favored-nation price—the lowest price anywhere in the world.”